{
    "Trade/Device Name(s)": [
        "Illumina MiSeqDx Cystic Fibrosis Clinical Sequencing Assay"
    ],
    "Submitter Information": "Illumina Inc.",
    "510(k) Number": "K132750",
    "Predicate Device Reference 510(k) Number(s)": [
        "K083845"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "PFS"
    ],
    "Summary Letter Date": "November 19, 2013",
    "Summary Letter Received Date": "September 3, 2013",
    "Submission Date": "August 30, 2013",
    "Regulation Number(s)": [
        "21 CFR 866.5900"
    ],
    "Regulation Name(s)": [
        "Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutation detection system"
    ],
    "Analyte Class(es)": [
        "genetic molecular"
    ],
    "Analyte(s)": [
        "CFTR gene mutations",
        "single nucleotide variants",
        "small InDels",
        "deep intronic mutations",
        "large deletions"
    ],
    "Specimen Type(s)": [
        "Genomic DNA from human peripheral whole blood"
    ],
    "Specimen Container(s)": [
        "K2EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Illumina MiSeqDx Instrument"
    ],
    "Method(s)/Technology(ies)": [
        "Targeted sequencing",
        "PCR-based amplification",
        "Sequencing by synthesis"
    ],
    "Methodologies": [
        "DNA sequencing",
        "Genomic variant analysis"
    ],
    "Submission Type(s)": [
        "Assay",
        "System",
        "Reagent",
        "Software",
        "Instrument",
        "Consumable"
    ],
    "Document Summary": "FDA 510(k) summary for Illumina MiSeqDx Cystic Fibrosis Clinical Sequencing Assay for targeted sequencing of CFTR gene mutations in peripheral blood using sequencing by synthesis on the MiSeqDx platform",
    "Indications for Use Summary": "Intended as an aid in the diagnosis of individuals with suspected cystic fibrosis, especially with atypical or non-classic presentation or when other mutation panels fail to identify both causative mutations; not for stand-alone diagnostic, fetal, pre-implantation, carrier, newborn, or population screening.",
    "fda_folder": "Immunology"
}